Zymeworks develops antibody-based medicines, with a focus on multispecific biologics for cancer and other serious diseases. Its proprietary Azymetric platform engineers antibodies that can bind multiple targets or sites in controlled geometries. The company advances its own pipeline and partners technology and product candidates with larger pharmaceutical firms.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 48.7 | — | 2.3 | — |
| Q3 2025 | 27.6 | — | -19.6 | — |
| Q4 2025 | 2.5 | — | -41.2 | — |
| Q1 2026 | 2.4 | — | -44.2 | — |
| Q2 2026 | 4.6 | -90.6% | -45 | -2,043% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Midera Food Processing, Inc. (MFP), Mineralys Therapeutics, Inc. (MLYS), Alvotech (ALVO), Establishment Labs Holdings Inc. (ESTA), Sunrun Inc. (RUN), Formula Systems (1985) Ltd. (FORTY)